Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Is ‘Aiming For The Sky’ With Vabysmo Commercial Launch

Executive Summary

CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.

You may also be interested in...



Fewer Drug Launches In 2022, But Standouts Among Them

Lilly's Mounjaro and Roche's Vabysmo appear on track to be fast blockbusters in a year that saw the fewest drug launches since 2016.

Europe’s Big Pharma Sails On Serenely Despite Choppy Economic Waters

The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.

BeiGene Is Keeping The Faith In IO/IO Combinations

Global head of R&D Lai Wang talked to Scrip about his expectations for a PD-1/TIGIT combination and remaining confident about the potential of IO/IO combinations in cancer despite disappointments. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel